65999-53-3

Basic information

• Product Name: 2-(2-bromophenyl)acetamide
• Synonyms: 2-(2-bromophenyl)acetamide
• CAS NO: 65999-53-3
• Molecular Formula: C₈H₈BrNO
• Molecular Weight: 214.061
• Mol File: 65999-53-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 370.7 °C at 760 mmHg
• Flash Point: 178 °C
• Appearance: /
• Density: 1.537 g/cm³
• Vapor Pressure: 1.09E-05mmHg at 25°C
• Refractive Index: 1.591
• CAS DataBase Reference: 2-(2-bromophenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-bromophenyl)acetamide(65999-53-3)
• EPA Substance Registry System: 2-(2-bromophenyl)acetamide(65999-53-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 65999-53-3(Hazardous Substances Data)

Usage

General Description

2-(2-bromophenyl)acetamide, also known as bromoacetanilide, is a chemical compound with the molecular formula C8H8BrNO. It is a white to off-white solid that is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. Bromoacetanilide is a brominated derivative of acetanilide, and its bromine substituent makes it a versatile building block for the production of various biologically active molecules. It is typically prepared by the bromination of acetanilide, followed by acetylation with acetic anhydride, and it is used in the synthesis of drugs such as chlorpropamide, an antidiabetic agent. Additionally, 2-(2-bromophenyl)acetamide has antimicrobial and anti-inflammatory properties, making it a valuable compound in the field of medicinal chemistry.

InChI:InChI=1/C8H8BrNO/c9-7-4-2-1-3-6(7)5-8(10)11/h1-4H,5H2,(H2,10,11)

Upstream product

• 103-81-1 Benzeneacetamide 
• 18698-97-0 ortho-bromophenylacetic acid 
• 7732-18-5 water 
• 7726-95-6 bromine 
• 55116-09-1 2-bromophenylacetyl chloride 
• 19472-74-3 2-(2-bromophenyl)acetonitrile 

Downstream Products

• 19472-74-3 2-(2-bromophenyl)acetonitrile 
• 103317-32-4 (2-bromophenyl)thioacetamide 
• 65185-58-2 2-(2-bromophenyl)ethanamine 
• 103-81-1 Benzeneacetamide 
• 1609551-53-2 2-(2-bromophenyl)-N-(quinolin-2-yl)acetamide 
• 1609551-52-1 2-(2-bromophenyl)-N-(isoquinolin-1-yl)acetamide 
• 1226855-91-9 2-(2',3',5'-trichlorobiphenyl-2-yl)acetamide 
• 16175-07-8 2-<2-(4-methylthiophenylthio)phenyl>acetic acid 
• 18698-97-0 ortho-bromophenylacetic acid 
• 89-51-0 Homophthalic acid 
• 65999-54-4 2-(4-Chlorphenylthio)-phenyl-acetamid 
• 65999-55-5 2-[2-(4-Methylsulfanyl-phenylsulfanyl)-phenyl]-acetamide 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

COMPOUNDS

Provided are benzoxazolinone sulfonamide derivatives that inhibit Na v1.7 activity, pharmaceutical compositions containing them and their use in therapy for the treatment of diseases mediated by Na v1.7 activity.

Exception to the ortho effect in palladium/norbornene catalysis

Out of the norm: The first deviation from the ortho effect in palladium/norbornene catalysis, as evidenced by the resulting products, is reported (see scheme). DFT calculations indicate that this deviation is likely to originate from a distortion, caused